Immunoassay Interference Blocker Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Immunoassay Interference Blocker Market Size

Immunoassay Interference Blocker Market size is set to expand at a notable CAGR from 2024 to 2032 driven by the increasing prevalence of chronic diseases coupled with the expanding geriatric population across the globe. According to the U.S. Census Bureau, the total population of adults aged 65 years and above is estimated to surpass 73.1 million by 2030. This rise may bolster the need for various therapies to accurately diagnose and treat life-threatening illnesses.
 

In recent years, the expenditure on healthcare and R&D programs has risen significantly. Such investments are likely to improve the adoption of the immunoassay interference blockers. Researchers are also escalating their efforts to improve clinical accuracy and enhance the quality of diagnosis of several diseases. Furthermore, several governments are showing their support for the rising demand from the healthcare sector by launching initiatives to improve the quality of medical infrastructure. 
 

Immunoassay Interference Blocker Market Trends

The rising prioritization of laboratories and diagnostic facilities on ethical and sustainable practices is surging the demand for interference blockers that do not rely on animal-derived components. Leading manufacturers are focusing on embracing animal-free products to actively contribute to decreasing the environmental impacts by optimizing energy and resource use while remaining compliant with changing regulatory demands. To cite an instance, in August 2023, Meridian Bioscience, Inc. developed two novel 100% animal-free immunoassay interference blockers, K-Block™, and Mouse-Free IgG with similar and higher performance compared to standard animal-derived blockers.
 

Immunoassay Interference Blocker Market Analysis

The market is divided into detection interferences, antibody interferences, and surface interferences. The industry revenue from the antibody interference blocker segment is anticipated to grow considerably through 2032. Antibody interference blockers are mainly used to decrease non-specific binding and other interferences, that specifically arise from anti-mouse antibodies, rheumatoid factor, and heterophilic antibodies. This is further leading to false-positive results in both paired and competitive monoclonal sandwich assays. The surging need to safeguard an assay's accuracy will contribute to the product adoption.  
 

The immunoassay interference blocker market from the competitive ELISA segment is estimated to record substantial gains between 2024 and 2032. This method uses crude or impure samples to selectively bind any antigen that may be present in the sample. Moreover, the ELISA technique offers high sensibility, specificity, and flexibility and is best suited for complex samples as it does not need to be purified before measurement.
 

The Europe immunoassay interference blocker market is projected to experience substantial progress from 2024 to 2032. Major pharmaceutical companies in the region are emphasizing R&D investments to improve the quality of their diagnosis and treatment. Several governments are also introducing favorable norms and programs to promote the manufacturing of diagnostic kits. For example, in July 2023, the Commission and the European Investment Bank established HERA Invest, a €100 million supplement to the Invest EU program to assist R&D in the most important cross-border health issues, funded by the EU4Health initiative. Such programs are expected to drive the development of novel immunoassay interference blockers in the region.
 

Immunoassay Interference Blocker Market Share

Through research, development, and strategic collaborations, leading immunoassay interference blocker industry players are enhancing product efficacy, innovating solutions, and expanding market presence for meeting the increasing demand for reliable diagnostics and ensuring accurate results in immunoassay tests. To illustrate, Meridian Bioscience stands out as a key market player for providing diagnostic solutions and innovative interference blockers for ensuring accurate and reliable immunoassay results.
 

Some of the notable players operating in the immunoassay interference blocker industry include-

• Roche Diagnostics
• AMS Biotechnology
• Aviva Systems Biology
• Bio-Rad Laboratories
• Abcam
• Scantibodies Laboratory
• Thermo Fisher Scientific
• Meridian Bioscience

Immunoassay Interference Blocker Industry News

• In 2023, Fapon Biotech presented its most recent advancements in in-vitro diagnostic and biopharmaceutical solutions at the Clinical Lab Expo and Scientific Meeting of the American Association of Clinical Chemistry.

What Information does this report contain?